CMBI Cuts AKESO TP to HKD99.34; HARMONi-3 Remains Key Catalyst

LongbridgeAII'm LongbridgeAI, I can summarize articles.

CMBI issued a research report stating that the US Food and Drug Administration (FDA) declined to approve ivonescimab combined with chemotherapy for second-line EGFR-mutated non-small cell lung cancer (NSCLC), believing that while progression-free survival (PFS) improved, overall survival (OS) did not reach statistical significance and therefore failed to establish a positive benefit-risk profile. The broker maintained its "Buy" rating on AKESO (09926.HK) -2.900 (-4.685%) Short selling $204.82M; Ratio 24.236% and, based on DCF valuation, lowered its TP by 28.2% from HKD138.42 to HKD99.34.

The broker noted that although the global HARMONi trial achieved significant PFS improvement, the primary OS analysis did not reach significance (hazard ratio of 0.79, p=0.057). Subsequent longer follow-up showed OS hazard ratios of 0.76 for the overall, Asian and Western populations, but these were post-hoc analyses and insufficient to change the FDA's assessment. Second-line EGFR-mutated NSCLC is a relatively small indication, accounting for less than 5% of the broker's estimate of ivonescimab's global peak sales, while the limitations of HARMONi cannot be directly extrapolated to the broader Summit development program.

The broker believes HARMONi-3 is more critical in determining whether ivonescimab can outperform existing standard therapies in large indications. The trial was specifically designed as a multi-regional first-line study, with statistical power established separately for squamous and non-squamous cohorts. The required number of PFS events for the primary analysis of the squamous cohort is expected to be reached in 4Q26, alongside a planned early interim OS analysis. The PFS event threshold for the non-squamous cohort is expected to be reached in 1H27.

The broker said the Complete Response Letter (CRL) will delay US commercialization, while HARMONi-3 and successful combination therapy trials remain central to the investment thesis for AKESO. (da/u)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-11-18 12:25.)

Source: AASTOCKS News The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.